+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 21 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and changes in disease activity of surzetoclax, an investigational oral drug, alone or combined with other treatments in adults with relapsed or refractory multiple myeloma MM, a disease where abnormal plasma cells grow in the bone marrow. This Phase 12 study is designed to find the best doses of surzetoclax in combination with other antimyeloma agents or alone, involving about 325 adult participants worldwide. The study includes multiple substudy phases to explore different drug combinations and dosing schedules for relapsedrefractory MM. Participants will receive surzetoclax with other drugs such as daratumumab given by injection, dexamethasone oral, pomalidomide oral, or etentamig intravenous infusion, depending on the substudy group. The study has dose escalation and optimization phases to determine the best doses of surzetoclax and other agents. Some participants will receive surzetoclax alone, while others receive it combined with other antimyeloma treatments. The total study duration is about 4.5 years. During the study, participants will attend regular visits at approved centers for medical assessments, blood tests, and monitoring of side effects. Researchers will track adverse events and measure disease activity changes. The main outcomes include dose-limiting toxicities and adverse events over up to 4.5 years. Secondary outcomes evaluate response rates, progression-free survival, duration of response, and overall survival. Participants will be closely monitored throughout the study period to assess treatment effects and safety.

Age: 18Years +All GendersPhase 1Phase 2
51 locations
E

Actively Recruiting

Researchers are studying ARGX-119, an intravenous drug, to find the right dose for children aged 5 to less than 18 years old with spinal muscular atrophy SMA. This phase 2 trial aims to understand how safe and effective ARGX-119 is, along with how it moves through the body and how the immune system reacts to it. The study focuses on improving neuromuscular junction function, which may help reduce muscle weakness and tiredness in these children. Participants will be randomly assigned to receive either ARGX-119 or a placebo through an IV during a 24-week double-blinded treatment period DBTP. All participants will continue their usual SMA treatments during this time. After finishing the DBTP, those who qualify can enter an open-label extension where everyone receives ARGX-119 IV for up to about two years. During the study, participants will have regular assessments including safety checks for adverse events, physical tests like the 6-minute walk test, and blood tests to measure drug levels and immune response. Researchers will track muscle strength changes and monitor participants for up to 124 weeks to evaluate long-term effects. This comprehensive monitoring helps understand the drugs impact and safety over time.

Age: 5Years - 17YearsAll GendersPhase 2
28 locations
E

Actively Recruiting

Researchers are evaluating how well the 20-valent pneumococcal conjugate vaccine 20vPnC works against pneumonia caused by seven new types of the Streptococcus pneumoniae bacteria. This study focuses on adults aged 65 years and older who are hospitalized with pneumonia confirmed by chest imaging. The study aims to compare the presence of pneumonia caused by these specific bacteria types in people vaccinated with 20vPnC versus those with pneumonia caused by other bacteria or strains. This observational study involves adults 65 years and older hospitalized with radiologically-confirmed community-acquired pneumonia RADCAP. Participants will provide a urine sample for testing pneumococcal bacteria using BinaxNOW and specific urinary antigen detection assays UAD-1 and UAD-2. Cases are identified by detection of the seven additional bacteria types in 20vPnC beyond the previous 13-valent vaccine, while controls include other pneumonia cases without these serotypes. No treatment is given as part of the study. Participants will be involved for about 1 to 2 days for urine sample collection and providing medical history. Researchers will collect detailed information on illness and hospital stay up to 30 days through medical record review. The main outcome measured is the effectiveness of 20vPnC against pneumonia caused by the seven additional bacterial types over approximately 55 months. Other clinical features and pneumonia types will also be reviewed during this period.

Age: 65Years +All Genders
54 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of ponsegromab combined with systemic chemotherapy compared to chemotherapy plus placebo for adults with metastatic pancreatic ductal adenocarcinoma mPDAC who have cachexia, a condition causing significant weight loss and fatigue. This Phase 2b3, randomized, double-blind study involves adult participants who have completed initial chemotherapy cycles and aims to improve treatment outcomes for this challenging condition. Participants will receive either one of two doses of ponsegromab or a placebo alongside first-line chemotherapy regimens consisting of nab-paclitaxel plus gemcitabine or FOLFIRINOX. The study intervention is given as a subcutaneous injection every four weeks. After an initial Phase 2b period where doses are evaluated, the study continues into Phase 3 with the selected ponsegromab dose or placebo. Participants may also join an optional open-label extension to receive ponsegromab for up to 12 months after the double-blind phase ends. During the study, participants will have tumor assessments approximately every 6 to 8 weeks by independent radiologists. The research team will monitor body weight changes, physical activity, quality of life measures, safety events, and survival outcomes over the course of the trial, which may last up to several years. Caregiver quality of life is also evaluated in an optional sub-study. Participants health and treatment effects will be closely followed until the studys completion in 2029.

Age: 18Years +All GendersPhase 2Phase 3
230 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
C

Actively Recruiting

Researchers are studying how to best monitor pancreatic cysts and identify biomarkers that may signal the risk of these cysts developing into pancreatic cancer. The study compares two different monitoring approaches with varying frequencies, aiming to learn which method and biomarkers help improve patient outcomes. This observational study focuses on adults aged 50 to 75 who have pancreatic cysts detected by imaging. Participants undergo either low-intensity or high-intensity surveillance programs. The low-intensity group receives MRI, CT, or endoscopic ultrasound EUS scans initially and at intervals up to every two years depending on findings. The high-intensity group has more frequent imaging based on cyst size, including regular MRI, CT, and EUS scans. Blood samples, biopsies, and fine-needle aspirations may also be collected as needed. The study follows patients for 5 years from enrollment. During the trial, participants have regular imaging tests such as MRI, CT, and EUS, along with blood sample collections to assess biomarkers related to cyst changes. Researchers monitor clinical outcomes including the development of worrisome or high-risk features, quality of life, anxiety, financial distress, and healthcare costs. The study also tracks adherence to surveillance and surgical outcomes. Follow-up continues for 5 years to capture long-term results and identify factors linked to pancreatic cyst progression.

Age: 50Years - 75YearsAll Genders
429 locations
R

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of zeleciment basivarsen DYNE-101 for treating myotonic dystrophy type 1 DM1. This phase 3 study includes participants diagnosed with DM1 confirmed by genetic testing and aims to assess the impact of DYNE-101 on physical function and disease symptoms. Participants are randomly assigned to receive either DYNE-101 or a matching placebo through intravenous infusion every 8 weeks during a 48-week placebo-controlled period. Following this, all participants enter a 24-week long-term extension where those initially on placebo switch to DYNE-101, and those on DYNE-101 continue the treatment. An Independent Data Monitoring Committee oversees safety and tolerability throughout the study. Participants undergo evaluations including the 5 Times Sit-To-Stand test as the primary outcome and various secondary measures such as hand opening time, muscle strength tests, walking speed, and patient and clinician global impressions. Blood samples are collected to monitor drug levels and immune responses. The total participation time may last up to approximately 80 weeks, including screening, treatment, and long-term follow-up assessments.

Age: 16Years +All GendersPhase 3
43 locations
S

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of zeleciment rostudirsen DYNE-251, given intravenously every 4 weeks, in ambulatory male children and adolescents aged 4 to 18 years with Duchenne muscular dystrophy DMD who have a specific mutation suitable for exon 51 skipping. This Phase 3 study aims to provide important information about this treatment option for this group of patients with DMD. The study includes three distinct periods a Screening period lasting up to 6 weeks, a Placebo-Controlled Period of 72 weeks where participants are randomly assigned to receive either zeleciment rostudirsen or placebo every 4 weeks, and an open-label Long-Term Extension Period of up to 96 weeks during which all participants receive the study drug every 4 weeks. This design allows researchers to compare the treatment to placebo and then assess longer-term effects. Participants will be closely monitored throughout the study with regular assessments including the primary outcome of Rise From Floor RFF velocity measured at baseline and Week 73. Various secondary measures such as walking speed, stair climbing ability, lung function, patient global impressions, blood creatine kinase levels, and safety through adverse event monitoring and blood drug levels will be collected up to Week 169 or study completion. The total study duration including the extension is up to approximately 168 weeks. This thorough evaluation helps understand the treatments impact and safety over time.

Age: 4Years - 18YearsMALEPhase 3
1 location
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations

1-10 of 21

1